Lunit is scrapping the Volpara Health Technologies name and folding the breast-imaging software maker into a single Lunit brand, a consolidation meant to turn screening and oncology AI into one connected platform and tighten execution in the U.S., Europe, Oceania and Asia. 

The move completes the integration that began with Lunit’s 2024 Volpara acquisition and shifts more commercial work to regional hubs while Seoul concentrates on research and new products.

The company says the combined portfolio now stretches from breast risk prediction and imaging quality to early detection and data-driven precision medicine, reaching more than 10,000 providers in over 65 countries. 

The strategy aims to give Lunit a clearer edge in a crowded market that includes breast-imaging AI players such as Kheiron, ScreenPoint and Vara, and oncology data and pathology AI vendors like Tempus and PathAI.

“By bringing Volpara under the Lunit brand, we’re uniting our technologies, teams, and mission to deliver a connected ecosystem that transforms how cancer is detected and treated worldwide,” said Brandon Suh, CEO of Lunit. “This marks the start of a new era of collaboration and impact across every stage of cancer care.”

A reorganized unit called Lunit International will absorb former Volpara operations and lead business development and customer engagement across those regions. Lunit said parts of its global sales organization will shift into those hubs to sharpen local execution, while headquarters focuses on pipeline and platform integration. The company also introduced a redesigned website reflecting the single-brand structure.